Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The main purpose of the study is find whether the addition of aldosterone antagonist,
spironolactone to dual renin-angiotensin-aldosterone system blockade involving angiotensin
converting enzyme inhibitor and AT-1 angiotensin II receptor blocker leads to the reduction
of proteinuria, main prognostic marker of chronic kidney disease progression.